Indian Drugs and Pharmaceuticals Limited
State-owned pharmaceutical company in India
Indian Drugs and Pharmaceuticals Limited (IDPL) is a public sector undertaking in India that was established to achieve self-sufficiency in the field of pharmaceuticals. It was founded in 1961 and is headquartered in New Delhi.
History[edit]
The establishment of IDPL was a significant step in the Indian government's efforts to promote the domestic production of pharmaceuticals and reduce dependency on imports. The company was set up with the assistance of the Soviet Union, which provided technical and financial support. The primary objective was to manufacture essential drugs and make them available at affordable prices to the Indian population.
IDPL played a crucial role in the development of the pharmaceutical industry in India. It was instrumental in the production of bulk drugs and formulations, which laid the foundation for the growth of the private pharmaceutical sector in the country.
Operations[edit]
IDPL operates several manufacturing facilities across India, including major plants in Hyderabad, Rishikesh, and Gurgaon. These facilities are involved in the production of a wide range of pharmaceutical products, including antibiotics, analgesics, and anti-inflammatory drugs.
The company has faced several challenges over the years, including financial difficulties and competition from the private sector. Despite these challenges, IDPL continues to be a key player in the Indian pharmaceutical industry, contributing to the availability of affordable medicines.
Products[edit]
IDPL manufactures a variety of pharmaceutical products, including:
- Antibiotics
- Analgesics
- Anti-inflammatory drugs
- Vitamins and nutritional supplements
The company focuses on producing generic drugs to ensure that essential medicines are accessible to the general population at reasonable prices.
Challenges and Future Prospects[edit]
IDPL has faced numerous challenges, including financial constraints and the need for modernization of its facilities. The company has been under financial stress due to accumulated losses and has been exploring various options for revival, including strategic partnerships and government support.
The future prospects of IDPL depend on its ability to modernize its operations, improve efficiency, and compete with private sector companies. The Indian government has been considering various measures to revitalize IDPL, recognizing its importance in ensuring drug security in the country.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian